Vemurafenib is indicated in monotherapy for the treatment of adult patients with BRAF-V600-mutation-positive unresectable or metastatic melanoma.

...- Histologically confirmed cancers (excluding melanoma and papillary thyroid cancer) with a BRAF V600 mutation and that are resistant to standard therapy or for which standard or curative therapy does...

...- Patients from whom paired melanoma biopsies are planned must have a V600E+ BRAF mutation confirmed prior to the administration of PLX4032...

...- Signed written informed consent - Recheck the results of histological studies and paraffin blocks - Histologically confirmed cancer that is either Stage IIIc (unresectable) or ---Stage IV (metastatic), and determined to be BRAF V600E or V600K mutation-positive by the local laboratory. ...

…partial or complete response and tumor regression (Table 2 and Fig. 2 and ​and3, and Table S3 and Fig. S2 and S3 in the Supplementary Appendix), and prolonged disease stabilization (Fig. S4 in the Supplementary Appendix) were observed in several tumor types, including non–small-cell lung cancer (8 partial responses in the cohort of 20 patients), Erdheim–Chester disease or Langerhans’-cell histiocytosis (1 complete and 5 partial responses in the cohort of 18 patients), anaplastic thyroid cancer (1 complete and 1 partial response in the cohort of 7 patients), cholangiocarcinoma (1 partial response in the cohort of 8 patients), with anecdotal responses in patients with salivary-duct cancer, clear-cell sarcoma, low-grade serous ovarian cancer, glioblastoma, anaplastic ependymoma, pancreatic cancer, and carcinoma of unknown primary type (supplimentary info).

Of the 26 patients with BRAF V600 mutations (all V600E), objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%)…